中文名稱BMS-986165中文同義詞化合物BMS-986165;BMS-986165;BMS986165;BMS986165;DEUCRAVACITINIB;氘可來替尼;氘可來昔替尼;德烏拉西丁;6-[(環(huán)丙基羰基)氨基]-4-[[2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基]氨基]-N-(甲基-D3)-3-噠嗪甲酰胺;氘可來替尼(換品名開票)英文名稱BMS-986165英文同義詞Tyk2-IN-4;TYK2-IN-4;BMS986165;BMS-986165;BMS986165;6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide;Deucravacitinib;Deucravacitinib(BMS986165);Deucravacitinib(TYK2-IN-4;6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide;DeucravacitinibQ:WhatisDeucravacitinibQ:WhatistheCASNumberofDeucravacitinibCAS號1609392-27-9分子式C20H22N8O3

BMS-986165性質(zhì)儲存條件Storeat-20°C溶解度DMF:1mg/ml;DMSO:1mg/Chemicalbookml;DMSO:PBS(pH7.2)(1:2):0.33mg/ml形態(tài)Acrystallinesolid

用途BMS-986165是一種新型口服選擇性TYK2抑制劑，該藥所具有的獨(dú)特作用機(jī)制有望提供一種有前景的口服選擇，幫助患者有效控制其銀屑病。